Business of Pharmacy Forum
Experience
About
Our People
Insights
Contact Us
Visante
Our Services
Hospitals, Health Systems & Other Providers
Pharmacy Strategic Review & Optimization
340B Program Performance
Specialty Pharmacy
Infusion Care Services
Pharmacy Revenue Cycle
Pharmacy Supply Chain
Consolidated Pharmacy Service Centers
Pharmacy Operational Performance
Compounding Excellence
Drug Diversion
Employee Pharmacy Benefit Design
Compliance Solutions
Pharmaceutical & Healthcare Technology
Strategic Planning
Advisory Boards
Critical Assessments & Mock Committees
Sales & Marketing Support
Implementation Support
Ad Hoc Support
Managed Care & Government Programs
Medicare
Medicaid
Health Exchanges
Health Plans/Employers
Pharmacy Benefit Management
Commercial Acquisition and Valuation
Acquisition Diligence and Valuation
503A and 503B Pharmacy Acquisition
Experience
About
Our People
Insights
Blog
Podcasts
Videos
Webinars
Newsletter
Conferences
Announcements
Publications
Contact Us
us
canada
uk
Our Services
Hospitals, Health Systems & Other Providers
Pharmacy Strategic Review & Optimization
340B Program Performance
Specialty Pharmacy
Infusion Care Services
Pharmacy Revenue Cycle
Pharmacy Supply Chain
Consolidated Pharmacy Service Centers
Pharmacy Operational Performance
Compounding Excellence
Drug Diversion
Employee Pharmacy Benefit Design
Compliance Solutions
Pharmaceutical & Healthcare Technology
Strategic Planning
Advisory Boards
Critical Assessments & Mock Committees
Sales & Marketing Support
Implementation Support
Ad Hoc Support
Managed Care & Government Programs
Medicare
Medicaid
Health Exchanges
Health Plans/Employers
Pharmacy Benefit Management
Commercial Acquisition and Valuation
Acquisition Diligence and Valuation
503A and 503B Pharmacy Acquisition
Experience
About
Our People
Insights
Blog
Podcasts
Videos
Webinars
Newsletter
Conferences
Announcements
Publications
Contact Us
Business of Pharmacy Forum
Experience
About
Our People
Insights
Contact Us
Insights
Visante
/
Visante Insider – October 2019
Newsletter
Visante Insider – October 2019
Published date: October 17, 2019
In this edition
of the Visante Insider:
USP gives breathing room
Increased scrutiny builds pressure on admin
CMS not giving up on 340B-based payment cuts
Important notice from Genentech re: Emicizumab (HEMLIBRA)
Important notice from DEA
Gene Therapy: Significant Therapeutic Value with Significant Cost
Share this:
Visante 
